Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks reported Q2 2026 revenue of $20 million, a 48% decrease year-over-year, with a GAAP net loss of ($57) million and Adjusted EBITDA loss of ($36) million. Despite the financial decline, the company announced significant strategic wins, including government contracts to build autonomous labs at MIT, Caltech, Northwestern, and the University of Maryland. Ginkgo also highlighted the rapid scaling of its Nebula autonomous lab and the successful launch of its ADME-One service, which has already secured 17 customers.

Ginkgo Bioworks Holdings, Inc. announced it will host a presentation and Q&A session to review its business performance for the second quarter ended June 30, 2026. The event is scheduled for Wednesday, August 5, 2026, at 4:30 p.m. ET. Details and a webcast link will be available on the company's investor relations website, and shareholders can submit questions in advance.

Ginkgo Bioworks completed the divestiture of its Biosecurity business on April 3, 2026, receiving a minority equity interest in the purchaser. For Q1 2026, the company reported a net loss of $82.6 million, an improvement from $91.0 million in Q1 2025. Revenue from continuing operations decreased significantly to $19.5 million from $38.2 million year-over-year. The company also continued its restructuring plan, which substantially concluded workforce reductions by December 31, 2025, and is now focused on facility consolidation.

Ginkgo Bioworks Holdings, Inc. (DNA) announced its 2026 Annual Meeting of Shareholders will be held virtually on Thursday, June 11, 2026, at 8:00 a.m. Eastern Time. Shareholders of record as of April 15, 2026, are eligible to vote on proposals including the election of six director nominees, the ratification of Deloitte & Touche LLP as the independent auditor for fiscal year 2026, and an advisory vote on executive compensation. Director Shyam Sankar will not be standing for re-election, leading to a reduction in board size from seven to six directors.

Ginkgo Bioworks Holdings, Inc. announced its 2026 Annual Meeting of Shareholders will be held virtually on Thursday, June 11, 2026, at 8:00 a.m. Eastern Time. Shareholders of record as of April 15, 2026, are eligible to vote on proposals including the election of six director nominees, the ratification of Deloitte & Touche LLP as the independent registered public accounting firm, and an advisory vote on executive compensation. Current Board Chair Shyam Sankar is not seeking re-election, leading to a reduction in board size from seven to six directors, and Ross Fubini is expected to chair the Compensation Committee.

Ginkgo Bioworks Holdings, Inc. (DNA) announced the completion of the previously disclosed transaction to divest its Biosecurity segment on April 3, 2026. The company's wholly-owned subsidiary, Ginkgo Bioworks, Inc., contributed substantially all operations of Ginkgo Biosecurity, LLC to Tower Biosecurity, Inc. (also known as Perimeter Systems, Inc.). In exchange, Ginkgo received shares representing approximately 20% of Tower Biosecurity's fully diluted equity, indicating a strategic partnership or continued interest in the divested entity's future. This divestiture meets the criteria for discontinued operations under Accounting Standards Codification 205-20, necessitating the inclusion of unaudited pro forma financial statements for the years ended December 31, 2025, 2024, and 2023 in the current report.